艾昆纬-推进精准肿瘤学-美国肿瘤学生物标志物检测趋势.pdfVIP

AdvancingPrecision

Oncology

TrendsinOncologyBiomarkerTestingintheU.S.

MARCH

2026

Introduction

Overthelasttwodecades,advancesincellularandmolecularunderstandingof

cancerhavesignificantlyaccelerated,leadingtobettercharacterizationoftumor

biology.Thishaspavedthewayforatransitiontowardsincreasinguseoftargeted

therapeuticsinoncology.Predictivebiomarkersenabletheuseofthesetherapies.

However,gapsremaininachievingoptimalbiomarkertestingacrosstumortypes,

potentiallyresultingineligiblepatientsnotreceivingtimelytreatment.

PriorIQVIAInstituteresearchpublishedin2020Thereportconcludeswithactionsthatstakeholders

identifiedmajorbarriersthatlimitbiomarkertestingforsuchasphysicians,laboratorydirectors,andhospital

solidtumorsintheU.S.Theresearchassessedbiomarkersystemscanpotentiallyutilizetoensureeligible

testingevolutionovertimeandofferedsolutionstohelppatientsaretestedandsubsequentlytreatedwith

reducetheidentifiedtestingbarriersinoncology.appropriateinterventions.

ThepurposeofthisreportistounderstandhowtheThestudywasproducedindependentlybythe

biomarkertestinglandscapehaschangedsincethatIQVIAInstituteforHumanDataScience.Fundingfor

publication.InadditiontoNSCLC—whichwasthethisworkandreporthasbeenprovidedbyAstraZeneca.

primarytumoroffocusforthe2020report—ThecontributionstothisreportofHeenaDarira,

testingratesinbreast,ovarian,andprostatecancersSarahFrieman,EshaHase,JenKarweit,andothersat

areincluded.InsightsobtainedfromoncologistsIQVI